INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma
Courtesy of Omega

INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma

Mahesh Karande, the President and CEO of Omega Therapeutics, is incredibly passionate about epigenetics. And it shows: in the work that he and his team do, in the therapies they…

Continue Reading INTERVIEW: Omega Therapeutics’ Mahesh Karande Discusses OTX-2002 for Hepatocellular Carcinoma
Cemiplimab Still Safe and Effective for cSCC, Study Shares
https://pixabay.com/en/vials-science-liquids-ionic-1781316/

Cemiplimab Still Safe and Effective for cSCC, Study Shares

  So far, the Phase 2 EMPOWER-CSCC-1 clinical study has evaluated cemiplimab (also known as Libtayo) in individuals with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). Data from…

Continue Reading Cemiplimab Still Safe and Effective for cSCC, Study Shares
Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)
Photo courtesy of Brittany

Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)

Before you read further, make sure to check out Part 1 of our interview, where Brittany discusses what non-small cell lung cancer (NSCLC) is, her diagnostic journey, and how she learned that…

Continue Reading Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 2)
Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)
Photo courtesy of Brittany

Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)

On the one-year anniversary of her RET+ non-small cell lung cancer (NSCLC) diagnosis, 37-year-old Brittany Hawkins had spent some time reflecting on her journey. When she was just seventeen years…

Continue Reading Advocating for Cancer Biomarker Testing: How Brittany Turned her RET+ NSCLC Diagnosis into Action (Pt. 1)
Mapping Acute Lymphoblastic Leukemia (ALL) Subtypes: An Interview with Todd Druley of Mission Bio (Pt. 2)
Photo: Todd Druley, Mission Bio

Mapping Acute Lymphoblastic Leukemia (ALL) Subtypes: An Interview with Todd Druley of Mission Bio (Pt. 2)

Don't forget to read Part 1 of our interview, where Todd discusses what acute lymphoblastic leukemia (ALL) is and why it is so important to raise awareness for ALL and other cancers. Today,…

Continue Reading Mapping Acute Lymphoblastic Leukemia (ALL) Subtypes: An Interview with Todd Druley of Mission Bio (Pt. 2)
Mapping Acute Lymphoblastic Leukemia (ALL) Subtypes: An Interview with Todd Druley of Mission Bio (Pt. 1)
Photo: Todd Druley, Mission Bio

Mapping Acute Lymphoblastic Leukemia (ALL) Subtypes: An Interview with Todd Druley of Mission Bio (Pt. 1)

Did you know that September is Childhood Cancer Awareness Month? Although September has just passed, it is still important to raise awareness of the many different forms of childhood cancer…

Continue Reading Mapping Acute Lymphoblastic Leukemia (ALL) Subtypes: An Interview with Todd Druley of Mission Bio (Pt. 1)